Management of liver metastases from gastric carcinoma: Where is the evidence?

##plugins.themes.academic_pro.article.sidebar##

Published Jan 22, 2013
Download
pdf
Vol. 91 No. 1 (2013): Issue Jan 2013

##plugins.themes.academic_pro.article.main##

Hichem Jerraya
Ahmed Saïdani
Mehdi Khalfallah
Ibtissem Bouasker
Ramzi Nouira
Chedly Dziri

Abstract

Background: Liver metastases of gastric carcinoma are often the synonym of advanced neoplastic disease which has long justified the indication of palliative chemotherapy. However, inspired by the good results of the management of liver metastases of colorectal cancers,several surgeons have focused on the treatment of liver metastases of gastric carcinoma. The different therapeutic modalities used are surgery, radiofrequency ablation, hepatic arterial infusion and palliative gastrectomy.
Aims: To provide evidence based answer to the following questions regarding liver metastases from gastric carcinoma:
1. What is the indication of surgery?
2. Does radiofrequency ablation useful?
3. What is the contribution of the hepatic arterial infusion?
4. Is there any benefit to palliative gastrectomy?
Methods: A literature search on PubMed database over the period from January 1990 to December 2011 was conducted using as key words "gastric cancer" and "liver metastases".
Results: Surgery of a single liver metastasis smaller than 5 cm and not associated with another metastatic site offers better results in terms of 5-year survival rate than palliative chemotherapy. Intra hepatic arterial chemotherapy offers an alternative to surgery in inoperable patients and can be proposed as neo adjuvant treatment to surgery. The interest of radiofrequency ablation and palliative gastrectomy remains unproven.
Conclusion: Surgery is a good indication for single liver metastasis of gastric carcinoma less than 5 cm and not associated with another extra hepatic metastasis.

Keywords:

Gastric cancer; hepatic metastases; hepatic resection; treatment

##plugins.themes.academic_pro.article.details##

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
  2. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
  3. Leong T. Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 2005; 21: 673-8.
  4. Okano K, Maeba T, Ishimura K et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235: 86-91.
  5. Sakamoto Y, Ohyama S, Yamamoto J, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 2003; 133: 507-11.
  6. Koga R, Yamamoto J, Ohyama S, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007; 37: 836-42.
  7. Cheon SH, Rha SY, Jeung HC, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008; 19: 1146-53.
  8. Ueda K, Iwahashi M, Nakamori M, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009; 394: 647-53.
  9. Kumagai K, Shimizu K, Yokoyama N et al. Gastrointestinal cancer metastasis and lymphatic advancement. Surg Today 2010; 40: 301-6.
  10. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl 3: S49-S58.
  11. Makino H, Kunisaki C, Izumisawa Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 2010; 30: 2367-76.
  12. Guide méthodologique. Analyse de la littérature et gradations des recommandations. Agence nationale d'accréditation et d'évaluation en santé (Anaes). 2000
  13. Bines SD, England G, Deziel DJ, et al. Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery. 1993; 114: 799- 805; discussion 804-5.
  14. Ochiai T, Sasako M, Mizuno S, et al. Hepatic resection for metastatic tumors from gastric cancer: analysis of prognostic factors. Br J Surg 1994; 81: 1175-8.
  15. Miyazaki M, Itoh H, Nakagawa K, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 1997; 92: 490-3.
  16. Fujii K, Fujioka S, Kato K, et al. Resection of liver metastasis from gastric adenocarcinoma. Hepatogastroenterology 2001; 48: 368-71.
  17. Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001; 181: 279-83.
  18. Saiura A, Umekita N, Inoue S, et al. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002; 49: 1062-5.
  19. Zacherl J, Zacherl M, Scheuba C, et al. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 2002; 6: 682-9.
  20. Shirabe K, Shimada M, Matsumata T, et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 2003; 50: 1560-63.
  21. Roh HR, Suh KS, Lee HJ, et al. Outcome of hepatic resection for metastatic gastric cancer. Am Surg. 2005; 71: 95-9.
  22. Sakamoto Y, Sano T, Shimada K et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534-539.
  23. Thelen A, Jonas S, Benckert C, et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol 2008; 34: 1328-34.
  24. Tiberio GA, Coniglio A, Marchet A, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol 2009; 35: 486-91.
  25. Choi SB, Song J, Kang CM, et al. Surgical outcome of metachronous hepatic metastases secondary to gastric cancer. Hepatogastroenterology 2010; 57: 29-34.
  26. Tsujimoto H, Ichikura T, Ono S, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010; 4: 406-13.
  27. Adam R, Chiche L. Chirurgie des métastases hépatiques de cancers non colo-rectaux, non endocrines. Rapport présenté au 107ème congrès français de chirurgie 2005. Monographie de l'Association française de Chirurgie - Ed Arnette.
  28. Nomura T, Kamio Y, Takasu N, et al. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg 2009; 16: 493-501.
  29. Kim HO, Hwang SI, Hong HP, Yoo CH. Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech 2009; 19: 208-12.
  30. Kim HR, Ha Cheon S, Lee KH, et al. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia 2010; 26: 305-15.
  31. An JY, Kim JY, Choi MG, et al. Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J 2008; 49: 1046-51.
  32. Iwahashi M, Tanimura H, Nakamori M, et al. Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: a preliminary study for liver metastases from esophageal and gastric cancer. Hepatogastroenterology 1999; 46: 2504-10.
  33. Ojima H, Ootake S, Yokobori T et al. Treatment of multiple liver metastasis from gastric carcinoma. World J Surg Oncol 2007; 5: 70.
  34. Yamakado K, Nakatsuka A, Takaki H, et al. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005; 16: 1747-51.
  35. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ. Value of palliative resection in gastric cancer. Br J Surg 2002; 89: 1438-43.
  36. Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg 2006; 30: 21-7.
  37. Samarasam I, Chandran BS, Sitaram V, et al. Palliative gastrectomy in advanced gastric cancer: is it worthwhile? ANZ J Surg 2006; 76: 60-3.
  38. Kim DY, Joo JK, Park YK, et al. Is palliative resection necessary for gastric carcinoma patients? Langenbecks Arch Surg 2008; 393: 31-5.
  39. Miyagaki H, Fujitani K, Tsujinaka T, et al. The significance of gastrectomy in advanced gastric cancer patients with non-curative factors. Anticancer Res 2008; 28: 2379-84.
  40. Lin SZ, Tong HF, You T, et al. Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol 2008; 134: 187-92.
  41. Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012; 19: 1231-9.
  42. Li C, Yan M, Chen J, et al. Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis. J Gastrointest Surg 2010; 14: 282-88.
  43. Shirabe K, Wakiyama S, Gion T, et al. Hepatic resection for treatment of liver metastases in gastric carcinoma: review of the literature. HPB 2006; 8: 89-92.
  44. Kakeji Y, Morita M, Maehara Y. Strategies for treating liver metastasis from gastric cancer. Surg Today 2010; 40: 287-94.
  45. Liu J, Chen L. Current status and progress in gastric cancer with liver metastasis. Chin Med J 2011; 124: 445-56.
  46. Kerkar SP, Kemp CD, Duffy A, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009; 10: 121.
  47. Chen MH, Yang W, Yan K, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005; 11: 6395-401.
  48. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg 2002; 137: 422-26.
  49. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008; 19: 847-51.
  50. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy? Semin Surg Oncol 1989; 5: 414-19.
  51. McCarter MD, Fong Y. Role for surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol 2001; 8: 38-43.